menu
    • menu
    [{"orgOrder":0,"company":"Genenta Science","sponsor":"ENEA Tech and Biomedical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ITALY","productType":"Cell and Gene therapy","year":"2025","type":"Financing","leadProduct":"Pembrolizumab","moa":"||IFNAR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genenta Science","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Intravenous Infusion","sponsorNew":"Genenta Science \/ ENEA Tech and Biomedical","highestDevelopmentStatusID":"7","companyTruncated":"Genenta Science \/ ENEA Tech and Biomedical"},{"orgOrder":0,"company":"Genenta Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Temferon","moa":"IFNAR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genenta Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genenta Science \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genenta Science \/ Inapplicable"},{"orgOrder":0,"company":"Menarini","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"MEN1611","moa":"||PI3K","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Menarini \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Menarini \/ Inapplicable"},{"orgOrder":0,"company":"Genenta Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Temferon","moa":"IFNAR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genenta Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genenta Science \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genenta Science \/ Inapplicable"},{"orgOrder":0,"company":"Genenta Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Temferon","moa":"IFNAR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genenta Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genenta Science \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genenta Science \/ Inapplicable"},{"orgOrder":0,"company":"Genenta Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Temferon","moa":"IFNAR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genenta Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genenta Science \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genenta Science \/ Inapplicable"},{"orgOrder":0,"company":"Genenta Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Temferon","moa":"IFNAR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genenta Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genenta Science \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genenta Science \/ Inapplicable"},{"orgOrder":0,"company":"Genenta Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Temferon","moa":"IFNAR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genenta Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genenta Science \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genenta Science \/ Inapplicable"},{"orgOrder":0,"company":"Genenta Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Temferon","moa":"IFNAR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genenta Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genenta Science \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genenta Science \/ Inapplicable"},{"orgOrder":0,"company":"Genenta Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Temferon","moa":"IFNAR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genenta Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genenta Science \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genenta Science \/ Inapplicable"},{"orgOrder":0,"company":"Genenta Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Temferon","moa":"IFNAR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genenta Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genenta Science \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genenta Science \/ Inapplicable"},{"orgOrder":0,"company":"Genenta Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Temferon","moa":"IFNAR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genenta Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genenta Science \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genenta Science \/ Inapplicable"},{"orgOrder":0,"company":"Genenta Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Temferon","moa":"IFNAR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genenta Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genenta Science \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genenta Science \/ Inapplicable"},{"orgOrder":0,"company":"Genenta Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Temferon","moa":"IFNAR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genenta Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genenta Science \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genenta Science \/ Inapplicable"},{"orgOrder":0,"company":"Philogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Fibromun","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Philogen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Philogen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Philogen \/ Inapplicable"},{"orgOrder":0,"company":"Philogen","sponsor":"University Hospital Z\u00fcrich","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Fibromun","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Philogen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Philogen \/ University Hospital Z\u00fcrich","highestDevelopmentStatusID":"7","companyTruncated":"Philogen \/ University Hospital Z\u00fcrich"},{"orgOrder":0,"company":"Menarini","sponsor":"Ryvu Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"MEN1703","moa":"PIM\/FLT3K","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Menarini \/ Ryvu Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Menarini \/ Ryvu Therapeutics"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Genenta Science

                            Italy arrow
                            Discovery Europe
                            Not Confirmed

                            Genenta Science

                            Italy arrow
                            Discovery Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Temferon,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : ENEA Tech and Biomedical

                            Deal Size : $21.9 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Genenta Secures €20M to Expand Pipeline Amid Brain Tumor Trial Success

                            Details : The financing will be used to advance their pipeline product Temferon, which is being evaluated for the treatment of methastatic Renal Cell Cancer.

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            March 19, 2025

                            Lead Product(s) : Temferon,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : ENEA Tech and Biomedical

                            Deal Size : $21.9 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Genenta Science

                            Italy arrow
                            Discovery Europe
                            Not Confirmed

                            Genenta Science

                            Italy arrow
                            Discovery Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Temferon

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Genenta Reprograms Tumor Microenvironment in GBM Patients

                            Details : Temferon uses ex-vivo gene transfer into autologous Tie2+ HSPCs to deliver immunomodulatory molecules via tumor-infiltrating monocytes; it's in phase 1/2 trials for uMGMT glioblastoma.

                            Product Name : Temferon

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            August 02, 2024

                            Lead Product(s) : Temferon

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Genenta Science

                            Italy arrow
                            Discovery Europe
                            Not Confirmed

                            Genenta Science

                            Italy arrow
                            Discovery Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Temferon

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments

                            Details : Temferon is a lenti-virus based hematopoietic stem progenitor cell immuno therapy enabling controlled and targeted interferon-α expression within cancers, which is investigated for the treatment of Glioblastoma Multiforme.

                            Product Name : Temferon

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            July 28, 2023

                            Lead Product(s) : Temferon

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Genenta Science

                            Italy arrow
                            Discovery Europe
                            Not Confirmed

                            Genenta Science

                            Italy arrow
                            Discovery Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Temferon

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The European Commission Grants Orphan Drug Designation to Temferon for Treatment of Glioma

                            Details : Temferon is a lenti-virus based hematopoietic stem progenitor cell immuno therapy enabling controlled and targeted interferon-α expression within cancers, which is investigated for the treatment of glioma.

                            Product Name : Temferon

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            June 29, 2023

                            Lead Product(s) : Temferon

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Philogen

                            Italy arrow
                            Discovery Europe
                            Not Confirmed

                            Philogen

                            Italy arrow
                            Discovery Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fibromun,Lomustine

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : University Hospital Zürich

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Philogen Publishes New Data on A Fibromun-Based Treatment Combination in Science Translational Medicine in Col...

                            Details : L19TNF is a fully-human immunomodulatory product consisting of the L19 antibody and TNF. The L19 antibody is specific to the EDB domain of fibronectin and mediates selective localization of TNF to the site of disease while sparing healthy organs.

                            Product Name : L19TNF

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            May 24, 2023

                            Lead Product(s) : Fibromun,Lomustine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : University Hospital Zürich

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Genenta Science

                            Italy arrow
                            Discovery Europe
                            Not Confirmed

                            Genenta Science

                            Italy arrow
                            Discovery Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Temferon

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FDA Grants Orphan Drug Designation to Temferon for Treatment of Glioblastoma Multiforme

                            Details : Temferon is a lenti-virus based hematopoietic stem progenitor cell immuno therapy enabling controlled and targeted interferon-alpha expression within cancers. Temferon modifies TEMs to release IFN-α inside tumors, rebuilding the immune system and counte...

                            Product Name : Temferon

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            February 03, 2023

                            Lead Product(s) : Temferon

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Genenta Science

                            Italy arrow
                            Discovery Europe
                            Not Confirmed

                            Genenta Science

                            Italy arrow
                            Discovery Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Temferon

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Genenta Data Presentation at AACR to Describe On-Target Biological Activity of Temferon™ in Unmethylated Gli...

                            Details : Data from 15 treated patients to be presented are expected to provide initial evidence of successful engraftment of Temferon-derived cells and of on-target biological activity in patients with uMGMT-GBM.

                            Product Name : Temferon

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            September 03, 2022

                            Lead Product(s) : Temferon

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Genenta Science

                            Italy arrow
                            Discovery Europe
                            Not Confirmed

                            Genenta Science

                            Italy arrow
                            Discovery Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Temferon

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Genenta to Host Expert Fireside Chat on Immuno Gene & Cell Therapy for Treatment of Solid Tumors

                            Details : Temferon, a lenti-virus based hematopoietic stem progenitor cell immuno-gene therapy enabling controlled and targeted interferon-α expression within cancers. Biologically delivered via engineered tumor-infiltrating monocytes, generates immune responses...

                            Product Name : Temferon

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            April 20, 2022

                            Lead Product(s) : Temferon

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Genenta Science

                            Italy arrow
                            Discovery Europe
                            Not Confirmed

                            Genenta Science

                            Italy arrow
                            Discovery Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Temferon

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Genenta Progresses to Higher Dosing Cohort in Temferon Phase 1/2a Clinical Trial in Glioblastoma Multiforme

                            Details : Ongoing trial of Temferon™ in glioblastoma multiforme patients who have an unmethylated MGMT gene promoter has escalated to next planned dose, on basis of no drug-limiting toxicities observed at lower doses, in previous three dose level cohorts.

                            Product Name : Temferon

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            April 05, 2022

                            Lead Product(s) : Temferon

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Genenta Science

                            Italy arrow
                            Discovery Europe
                            Not Confirmed

                            Genenta Science

                            Italy arrow
                            Discovery Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Temferon

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Genenta To Present Updated Phase I/II Data At Upcoming Scientific Congresses SNO AND ASH

                            Details : Temferon™ is based on ex-vivo gene transfer into autologous hematopoietic stem/progenitor cells to deliver immunomodulatory molecules directly via tumor-infiltrating monocytes/macrophages.

                            Product Name : Temferon

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            November 16, 2021

                            Lead Product(s) : Temferon

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth